Latest Breaking News On - ஆண்ட்ரூ லண்டன் - Page 4 : comparemela.com

New Data Show NEXTSTELLIS® Has Selective Impact On Endocrine Markers Compared With Common Combined Oral Contraceptives Results presented at the annual meeting of the International Society for the Study of Women s Sexual Health News provided by Share this article Share this article RALEIGH, N.C., March 6, 2021 /PRNewswire/  Mayne Pharma announced today new data showing treatment with NEXTSTELLIS®, 1 a novel, investigational combined oral contraceptive (COC) containing drospirenone (DRSP) and estetrol (E4), resulted in limited changes in endocrine markers, including lower increases in hormone binding globulins, compared with COCs based on ethinyl-estradiol (EE), the synthetic estrogen used in all but one of the marketed COCs. The data was presented at the annual meeting of the International Society for the Study of Women s Sexual Health (ISSWSH), held virtually in the U.S. from March 5-7. 

Scott richardsMayne pharmaKaren dombekMithra pharmaceuticalsJohns hopkins school of medicineDrug administrationInternational societySexual healthAndrew londonAssistant professorJohns hopkins schoolNew drug applicationஸ்காட் ரிச்சர்ட்ஸ்மேனே பார்மாகரேன் தொம்பேக்மித்ரா மருந்துகள்